| abstract |
The present invention relates to derivatives of 2-adamantylamine of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) and to the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, disorders lipid metabolism, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. |